Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Credit Rating
India Ratings & Research affirmed Marksans Pharma’s bank loan ratings (IND AA-/IND A1+) and revised the outlook to Positive from Stable for facilities of ₹195.75 crore.
Credit Rating Outlook
India Ratings & Research affirmed Marksans Pharma's bank loan ratings (IND AA-/IND A1+) and revised the outlook to Positive from Stable for bank facilities of ₹195.75 crore (intimation dated 09-Jun-2026).
Bearish
2
Neutral
6
Bullish
6
Bearish
3
Neutral
6
Bullish
37
Bearish
1
Neutral
0
Bullish
31
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1024.85 | 12,543 Cr | 22.22 | 3.76 | 0.49 | 16.94 | 22.33 | 14.17 | ||
250.50 | 11,313 Cr | 27.07 | 3.74 | 0.36 | 13.82 | 17.37 | 10.88 | ||
249.35 | 10,893 Cr | 68.18 | 3.74 | 0.00 | 7.07 | 13.01 | 4.44 | ||
4578.00 | 10,564 Cr | 40.96 | 27.51 | 1.63 | 62.53 | 75.60 | 47.15 | ||
542.30 | 10,540 Cr | 43.32 | 4.07 | 0.11 | 9.39 | 10.73 | 6.57 | ||
1680.00 | 10,279 Cr | 55.53 | 13.76 | 0.59 | 24.79 | 27.13 | 15.36 | ||
6190.00 | 10,271 Cr | 31.42 | 19.58 | 6.71 | 62.32 | 84.14 | 38.86 | ||
| Median: 7 Co. | — | 1024.85 | 10,564 Cr | 40.96 | 4.07 | 0.49 | 16.94 | 22.33 | 14.17 |
Marksans Pharma Ltd (MARKSANS) is currently trading at 250.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Marksans Pharma Limited is an integrated pharmaceutical company focused on research, manufacturing and global distribution of formulation products, with a dominant OTC/store-brand presence in the US and a strong front-end in the UK and Australia; the company operates four manufacturing units, four R&D centres and holds multiple accreditations including USFDA, MHRA, TGA and Health Canada. In Q3 FY26 Marksans reported operating revenue of ₹754.4 crore, a 10.6% YoY increase, EBITDA of ₹160.7 crore with a 21.3% margin, and 9M FY26 cash generation of ₹263.2 crore alongside a cash balance of ₹824.2 crore as of December 31, 2025, reflecting improved margins driven by raw material softness, FX tailwinds and operating leverage. Strategically, Marksans is actively expanding its regulated-market footprint: in Q3 FY26 it incorporated subsidiaries in Europe and Canada, continues to pursue Europe-focused M&A, and targets to double US store-brand OTC revenue while aiming for a revenue milestone of ₹3,000 crore and a medium-term INR 4,000 crore target within two to three years. Manufacturing and pipeline scale are core strengths: the firm reports aggregate manufacturing capacity of 26 billion units per annum, plans to double Indian low-cost capacity from 8bn to 16bn units, invested ₹62 crore in R&D in 9M FY26 (3% of revenue), and maintains a pipeline of 100+ products with 300+ ANDAs/MAs approved and 1,500+ SKUs across markets. Marksans combines a cash-positive balance sheet with disciplined capital allocation — including prior ₹372.4 crore equity from warrant conversion in 2023 — and a strong credit profile (CARE AA- / A1+), positioning the company to fund inorganic growth, scale manufacturing and pursue targeted product approvals in regulated markets.
Over the past 52 weeks, Marksans Pharma Ltd has traded between a low of ₹156.00 and a high of ₹270.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Marksans Pharma Ltd has a market capitalization of approximately 11,313.23. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Marksans Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 27.07 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 11,313.23 Cr, Marksans Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Marksans Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Marksans Pharma Ltd is 27.07. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The most significant announcement is the 'Biopharma Shakti' scheme, a ₹10,000 crore initiative aimed at making India a global biopharmaceutical manufacturing hub, which will strengthen the entire industry ecosystem.
Marksans Pharma Limited is an integrated pharmaceutical company focused on research, manufacturing and global distribution of formulation products, with a dominant OTC/store-brand presence in the US and a strong front-end in the UK and Australia; the company operates four manufacturing units, four R&D centres and holds multiple accreditations including USFDA, MHRA, TGA and Health Canada.
In Q3 FY26 Marksans reported operating revenue of ₹754.4 crore, a 10.6% YoY increase, EBITDA of ₹160.7 crore with a 21.3% margin, and 9M FY26 cash generation of ₹263.2 crore alongside a cash balance of ₹824.2 crore as of December 31, 2025, reflecting improved margins driven by raw material softness, FX tailwinds and operating leverage.
Strategically, Marksans is actively expanding its regulated-market footprint: in Q3 FY26 it incorporated subsidiaries in Europe and Canada, continues to pursue Europe-focused M&A, and targets to double US store-brand OTC revenue while aiming for a revenue milestone of ₹3,000 crore and a medium-term INR 4,000 crore target within two to three years.
Manufacturing and pipeline scale are core strengths: the firm reports aggregate manufacturing capacity of 26 billion units per annum, plans to double Indian low-cost capacity from 8bn to 16bn units, invested ₹62 crore in R&D in 9M FY26 (3% of revenue), and maintains a pipeline of 100+ products with 300+ ANDAs/MAs approved and 1,500+ SKUs across markets.
Marksans combines a cash-positive balance sheet with disciplined capital allocation — including prior ₹372.4 crore equity from warrant conversion in 2023 — and a strong credit profile (CARE AA- / A1+), positioning the company to fund inorganic growth, scale manufacturing and pursue targeted product approvals in regulated markets.
Pharmaceuticals & Biotechnology
Pharmaceuticals
11,356 Cr
High Risk
27.2
34.1
1.2
3.7
270.10
156.00
Sales CAGR
Profit CAGR
ROE
ROCE
